Key result
Lung cancer and hypertension multimorbidity linked to ~132% higher mortality over 25 years.
Why the study?
Temporal trends and demographic disparities in multimorbidity-related mortality among US patients with lung cancer and hypertensive diseases remained inadequately characterized.
Observational (n=274,959)
Yes
There has been a nearly three-fold increase in multimorbidity-related mortality among US patients with lung cancer and hypertensive diseases over the past 25 years, highlighting the need for integrated cardio-oncology care.
Answers are grounded in this paper and cite their sources.
May warrant enhanced cardio-oncology surveillance in lung cancer with hypertension; leaves open whether interventions reduce mortality.
e20694 Background: Multimorbidity, defined as the coexistence of two or more chronic conditions, poses major challenges to healthcare systems globally. Hypertension is a critical comorbidity in lung cancer patients contributing to cardiovascular complications through shared risk factors and treatment-related cardiotoxicity. Despite its clinical significance, temporal trends and demographic disparities in multimorbidity-related mortality among this population remain inadequately characterized. This study aims to identify patterns and correlations to guide healthcare interventions and policies and investigates trends in multimorbidity-related mortality among US patients with lung cancer and hypertensive diseases over two decades. Methods: We conducted a retrospective analysis using CDC WONDER database (1999-2023), including adults ≥25 years with hypertensive diseases (ICD-10: I10-I15) and lung cancer (C34) as causes of death. Age-adjusted mortality rates (AAMR) per 100,000 were calculated. Joinpoint regression identified trends via annual percentage change (APC) and average annual percentage change (AAPC). Results were stratified by sex, age, race/ethnicity, region, and urbanization. Results: From 1999-2023, 274,959 hypertension diseases-related deaths occurred among lung cancer patients. AAMR increased from 2.60 (95% CI: 2.52-2.67) to 6.03 (95% CI: 5.94-6.12), a 131.9% increase, with overall AAPC of 3.31% (95% CI: 2.26-4.37, p < 0.001). Joinpoint analysis identified: acceleration 1999-2001 (APC: 19.53%), increase 2001-2008 (APC: 3.74%), stabilization 2008-2018 (APC: -0.85%), resurgence 2018-2021 (APC: 9.20%), and plateau 2021-2023 (APC: -0.53%). Males had higher AAMRs (5.97 vs 3.92), but females showed steeper increases (AAPC: 3.52% vs 3.02%). Adults ≥65 years had highest AAPC (3.47%). White individuals had highest AAPC (3.91%), followed by Hispanic (3.75%), Black (1.29%), and Asian/PI (1.28%). The South exhibited highest regional AAPC (4.99%), followed by Midwest (2.65%) and Northeast (2.29%). Non-metropolitan areas exceeded metropolitan (AAPC: 4.76% vs 3.10%). Oklahoma (AAMR: 24.55), Mississippi (20.69), South Carolina (16.42) had highest state rates and Utah (1.40) has the lowest. Conclusions: This analysis demonstrates a nearly three-fold increase in multimorbidity-related mortality among lung cancer and hypertensive diseases patients over 25 years, with females, White populations, Southern states, and non-metropolitan areas showing pronounced increases. These findings emphasize the need for integrated cardio-oncology protocols and targeted interventions addressing geographic and demographic disparities.Targeted healthcare strategies are essential to address the specific needs of high-risk populations and ensure equitable access to healthcare resources.
No takes yet. Share an insight, caveat, or question.
Bathula et al. (2026) conducted an observational in Lung cancer and hypertensive diseases (n=274,959). Multimorbidity with lung cancer and hypertensive diseases was associated with a 131.9% increase in age-adjusted mortality rates over 25 years.
Synapse has enriched 10 related papers. Consider them for comparative context: